ADDXF Stock UPDATES Addex Pharma Ord (ADDXF) 4.4900 08/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Addex Pharma Ord (ADDXF) 4.4900 $ADDXF

Competitor Analysis: GLP-1 Receptor Agonists Development Pipeline Report 2014
M2 - Tue Aug 19, 9:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4zkt/competitor) has announced the addition of the "Competitor Analysis: GLP-1 Receptor Agonists" report to their offering. The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes and obesity. In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market. The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market. The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage - Additional comments with a hyperlink leading to the source of information. Key Topics Covered: 1. Selective GLP-1 Analogs for Metabolic Diseases - 2013 Sales of GLP-1 Analogs - Short-Acting Injectable GLP-1 Analogs - Long-Acting Injectable GLP-1 Analogs - Very Long-Acting Injectable GLP-1 Analogs - Oral Peptide-Based GLP-1 Analogs - Other Non-Injectable Peptide-Based GLP-1 Analogs - Oral Small Molecule GLP-1 Receptor Agonists 2. Selective GLP-1 Analogs for Non-Metabolic Diseases 3. Dual Target GLP-1 Analogs - GLP-1 and Insulin - GLP-1 and Glucagon - GLP-1 and GIP - GLP-1 and Gastrin/CCKB - GLP-1 and GLP-2 4. Corporate GLP-1 Receptor Agonist R&D Pipelines Companies Mentioned - Addex Pharmaceuticals - Amylin Pharmaceuticals - Arisaph Pharmaceuticals - Arisgen - Ascendis Pharma (Complex Biosystems) - Bio-ker - Biocompatibles International - ConjuChem - Dong-A Pharmaceutical - Eli Lilly - Emisphere Technologies - Faust Pharmaceuticals - GlaxoSmithKline - Hanmi Pharmaceuticals - Ipse - Mannkind - MDRNA (ex Nastech Pharmaceuticals) - Modigene - Novo Nordisk - OctoPlus - Oramed Pharmaceuticals - Pfizer - Proxima Concepts - Roche (& Chugai) - Rose Pharmaceuticals (ex Gastrotech) - Sanofi-Aventis - Teijin - Transition Therapeutics - TransTech Pharma - Unigene For more information visit http://www.researchandmarkets.com/research/7d4zkt/competitor

Osteoarthritis Pain - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8frj9r/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis Pain. - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genzyme Corporation Johnson & Johnson Allergan, Inc. Amgen Inc. Sanofi-Aventis Eli Lilly and Company BioDelivery Sciences International, Inc. Pfizer Inc. Purdue Pharma L.P. Teva Pharmaceutical Industries Limited Menarini Group BioChemics, Inc. Addex Pharmaceuticals Elite Pharmaceuticals, Inc. POZEN Inc. Array BioPharma Inc. Futura Medical plc. Transition Therapeutics Inc. Palau Pharma S.A Neurotune AG QRxPharma Limited and much more... For more information visit http://www.researchandmarkets.com/research/8f...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Endometriosis - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9zxrdh/endometriosis) has announced the addition of the "Endometriosis - Pipeline Review, H2 2013" report to their offering. 'Endometriosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Endometriosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Endometriosis. Scope - A snapshot of the global therapeutic scenario for Endometriosis. - A review of the Endometriosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Endometriosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Euroscreen S.A. Takeda Pharmaceutical Company Limited Neurocrine Biosciences, Inc. Astellas Pharma Inc. Kissei Pharmaceutical Co., Ltd. Bayer AG Addex Pharmaceuticals Evotec Aktiengesellschaft ValiRx Plc Repros Therapeutics Inc. DONGKOOK Pharmaceutical Co., Ltd. Camurus AB Lipicard Technologies Limited Orphagen Pharmaceuticals, Inc. Quatrx Pharmaceutical Company Peptron, Inc. PregLem SA EndoCeutics, Inc. Isifer AB For more information visit http://www.researchandmarkets.com/research/9z...ometriosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Urinary Incontinence - Pipeline Review, H2 2013
M2 - Fri Sep 06, 2:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gnq99s/urinary) has announced the addition of the "Urinary Incontinence - Pipeline Review, H2 2013" report to their offering. 'Urinary Incontinence - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Urinary Incontinence, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urinary Incontinence. Scope - A snapshot of the global therapeutic scenario for Urinary Incontinence. - A review of the Urinary Incontinence products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Urinary Incontinence pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Cook Medical Incorporated Allergan, Inc. Astellas Pharma Inc. Mitsubishi Tanabe Pharma Corporation Recordati S.p.A. Addex Pharmaceuticals Evotec Aktiengesellschaft Plethora Solutions Holdings plc Melior Discovery, Inc. Fate Therapeutics, Inc. Celogos Sinil Pharma Ltd. Beech Tree Labs, Inc. For more information visit http://www.researchandmarkets.com/research/gnq99s/urinary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Dystonia - Pipeline Review, H2 2013 Report Features Players such as Addex Pharmaceuticals and QRxPharma Limited
M2 - Thu Sep 05, 9:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vr9rld/dystonia) has announced the addition of the "Dystonia - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Dystonia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dystonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dystonia. Dystonia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Dystonia. - A review of the Dystonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dystonia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Addex Pharmaceuticals - QRxPharma Limited For more information visit http://www.researchandmarkets.com/research/vr9rld/dystonia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Global Spasticity Pipeline Review Report - Latest 2013 Edition
M2 - Wed Sep 04, 10:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrtp7w/spasticity) has announced the addition of the "Spasticity - Pipeline Review, H2 2013" report to their offering. 'Spasticity - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Spasticity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spasticity. Scope - A snapshot of the global therapeutic scenario for Spasticity. - A review of the Spasticity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Spasticity pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Spasticity Therapeutics Development - Ipsen S.A. - Novartis AG - Merz GmbH & Co. KGaA - Sun Pharmaceutical Industries Limited - Addex Pharmaceuticals - GW Pharmaceuticals plc - Sanochemia Pharmazeutika AG - Raptor Pharmaceuticals Corp. - Osmotica Pharmaceutical Corp. - Intec Pharma ltd. - Concert Pharmaceuticals, Inc. Drug Profiles - nabiximols - arbaclofen - NGX-426 - tezampanel - abobotulinumtoxinA - onabotulinumtoxinA - BGG-492 - ADX-71441 - SUN-09 - CTP-354 - baclofen ER - onabotulinumtoxinA For more information visit http://www.researchandmarkets.com/research/zrtp7w/spasticity

Gouty Arthritis (Gout) - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m6xk6h/gouty_arthritis) has announced the addition of the "Gouty Arthritis (Gout) - Pipeline Review, H2 2013" report to their offering. 'Gouty Arthritis (Gout) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gouty Arthritis (Gout), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout). Scope - A snapshot of the global therapeutic scenario for Gouty Arthritis (Gout). - A review of the Gouty Arthritis (Gout) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Gouty Arthritis (Gout) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned AstraZeneca PLC Teijin Pharma Limited Novartis AG Kissei Pharmaceutical Co., Ltd. Addex Pharmaceuticals BioCryst Pharmaceuticals, Inc. SANWA KAGAKU KENKYUSHO CO.,LTD. XOMA Ltd. Nippon Chemiphar Co., Ltd. Choongwae Pharma Corp LG Life Sciences, Ltd Metabolex, Inc Wellstat Therapeutics Corporation Opsona Therapeutics Ltd. PLx Pharma Inc. Antibe Therapeutics, Inc. Polaris Group For more information visit http://www.researchandmarkets.com/research/m6..._arthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Benign Prostatic Hyperplasia - Pipeline Review, H2 2013
M2 - Mon Sep 02, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r9fndv/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H2 2013" report to their offering. 'Benign Prostatic Hyperplasia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Benign Prostatic Hyperplasia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia. Scope - A snapshot of the global therapeutic scenario for Benign Prostatic Hyperplasia. - A review of the Benign Prostatic Hyperplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Benign Prostatic Hyperplasia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Eli Lilly and Company Light Sciences Oncology, Inc. Ipsen S.A. Aphios Corporation Astellas Pharma Inc. Chong Kun Dang Pharmaceutical Dong-A Pharmaceutical Co., Ltd. Addex Pharmaceuticals AEterna Zentaris Inc. IntelGenx Technologies Corp. Kaken Pharmaceutical Co.,Ltd. Karo Bio Nymox Pharmaceutical Corporation Quest PharmaTech Inc. Plethora Solutions Holdings plc Protox Therapeutics Inc. AndroScience Corporation NovaLead Pharma Pvt. Ltd. EndoCeutics, Inc. AmVac AG KAEL-GemVax Ausio Pharmaceuticals, LLC Se-cure Pharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/r9..._prostatic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/664sjs/reflux) has announced the addition of the "Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2013" report to their offering. 'Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease). Scope - A snapshot of the global therapeutic scenario for Reflux Esophagitis (Gastroesophageal Reflux Disease). - A review of the Reflux Esophagitis (Gastroesophageal Reflux Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Takeda Pharmaceutical Company Limited Eisai Co., Ltd. Ono Pharmaceutical Co., Ltd. Wockhardt Limited Shire Plc Addex Pharmaceuticals Flamel Technologies S.A. Yuhan Corporation Torrent Pharmaceuticals Limited Ahn-Gook Pharmaceutical Co., Ltd. aRigen Pharmaceuticals, Inc. Cempra Pharmaceuticals, Inc. Vecta Ltd. Sihuan Pharmaceutical Holdings Group Ltd. Reviva Pharmaceuticals Inc. RaQualia Pharma Inc. For more information visit http://www.researchandmarkets.com/research/664sjs/reflux About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Osteoarthritis - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkkfb7/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis. - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Osiris Therapeutics, Inc. Seikagaku Corporation Sanofi-Aventis Ablynx TiGenix NV Novartis AG Astellas Pharma Inc. Chong Kun Dang Pharmaceutical Chugai Pharmaceutical Co. Ltd Pfizer Inc. Menarini Group Merck KGaA Bone Medical Limited Addex Pharmaceuticals Can-Fite BioPharma Ltd. Medivir AB Mesoblast Ltd Calzada Limited NicOx SA and many more... For more information visit http://www.researchandmarkets.com/research/nk...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Duchenne Muscular Dystrophy - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dxghnf/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H2 2013" report to their offering. 'Duchenne Muscular Dystrophy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Duchenne Muscular Dystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy. Scope - A snapshot of the global therapeutic scenario for Duchenne Muscular Dystrophy. - A review of the Duchenne Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Duchenne Muscular Dystrophy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genzyme Corporation Johnson & Johnson Allergan, Inc. Amgen Inc. Sanofi-Aventis Eli Lilly and Company BioDelivery Sciences International, Inc. Pfizer Inc. Purdue Pharma L.P. Teva Pharmaceutical Industries Limited Menarini Group BioChemics, Inc. Addex Pharmaceuticals Elite Pharmaceuticals, Inc. POZEN Inc. Array BioPharma Inc. Futura Medical plc. Transition Therapeutics Inc. Palau Pharma S.A Neurotune AG QRxPharma Limited Iroko Pharmaceuticals, LLC and many more.... For more information visit http://www.researchandmarkets.com/research/dx...e_muscular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Women Infertility - Pipeline Review, H2 2013 Report Features Players such as Merck KGaA, EndoCeutics, Inc. and Quatrx Pharmaceutical Company
M2 - Thu Aug 08, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/ksmjh2/women_infertility) has announced the addition of the "Women Infertility - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Women Infertility - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Women Infertility, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Women Infertility. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Women Infertility. - A review of the Women Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Women Infertility pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - ASKA Pharmaceutical Co., Ltd - Access Pharmaceuticals, Inc. - Addex Pharmaceuticals - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Camurus AB - Crinetics Pharmaceuticals, Inc. - DONGKOOK Pharmaceutical Co., Ltd. - Dong-A Pharmaceutical Co., Ltd. - Euroscreen S.A. - Evotec Aktiengesellschaft - Ferring Pharmaceuticals, Inc. - Glycotope GmbH - IBSA Farmaceutici Italia Srl - Intas Pharmaceuticals Ltd. - Isifer AB - JCR Pharmaceuticals Co., Ltd. - Kissei Pharmaceutical Co., Ltd. - Lipicard Technologies Limited - Merck & Co., Inc. - Neurocrine Biosciences, Inc. - Orphagen Pharmaceuticals, Inc. - Pantec Biosolutions AG - Peptron, Inc. - PregLem SA - Reliance Life Sciences Pvt. Ltd. - Repros Therapeutics Inc. - Takeda Pharmaceutical Company Limited - Techpool Bio-Pharma Co., LTD. - Teva Pharmaceutical Industries Limited - Trophogen, Inc. - ValiRx Plc - Watson Pharmaceuticals, Inc. - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/ks...nfertility About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Psychosis - Pipeline Review, H2 2013 Report Features Players such as Addex Pharmaceuticals and Clera Inc.
M2 - Tue Aug 06, 12:02PM CDT
Research and Markets (http://www.researchandmarkets.com/research/plc8gk/psychosis) has announced the addition of the "Psychosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Psychosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Psychosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psychosis. Psychosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Psychosis. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Psychosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 ACADIA Pharmaceuticals Inc. Addex Pharmaceuticals Clera Inc. Evotec Aktiengesellschaft H Lundbeck A/S Newron Pharmaceuticals S.p.A. Reviva Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/plc8gk/psychosi About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2013
M2 - Wed Jun 19, 10:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qx39tm/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2013" report to their offering. 'Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD). Scope - A snapshot of the global therapeutic scenario for Post-Traumatic Stress Disorder (PTSD). - A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development

Obsessive-Compulsive Disorder - Pipeline Review, H1 2013 Report Features Players such as Omeros Corporation and Conformetrix Ltd
M2 - Thu Jun 06, 11:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jnsc8t/obsessivecompulsi) has announced the addition of the "Obsessive-Compulsive Disorder - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Obsessive-Compulsive Disorder - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Obsessive-Compulsive Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Obsessive-Compulsive Disorder. Obsessive-Compulsive Disorder - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. S

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2013 Featuring 16 Major Companies and 29 Drug Profiles
M2 - Thu Apr 18, 6:17AM CDT
Research and Markets has announced the addition of the Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2013 report to their offering. 'Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease). Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of

G-Protein Coupled Receptors (GPCRs) - Global Strategic Business Report
M2 - Fri Feb 15, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/zqvp3v/gprotein_coupled) has announced the addition of the "G-Protein Coupled Receptors (GPCRs) - Global Strategic Business Report" report to their offering. This report analyzes the Global market for G-Protein Coupled Receptors (GPCRs) in US$ Billion. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for this market. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. Key Topics Covered I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. G-Protein Coupled Receptors (Gpcr) - A Conceptual Overview 3. Recent Industry Activity 4. Focus On Select Global Players 5. Global Market Perspective III. Competitive Landscape Companies Mentioned The report profiles 43 companies including - 7TM Pharma A/S - Acadia Pharmace

Anxiety Disorders - Pipeline Review, H2 2012
M2 - Thu Jan 17, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/nw7hxn/anxiety_disorders) has announced the addition of Global Markets Direct's new report "Anxiety Disorders - Pipeline Review, H2 2012" to their offering. This report provides information on the therapeutic development for Anxiety Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anxiety Disorders. Anxiety Disorders - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Anxiety Disorders. - A review of the Anxiety Disorders products under development by companies and universities/research institutes base

Addiction - Pipeline Review: Latest updates and review of key players
M2 - Wed Jan 09, 4:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/vd2xs3/addiction) has announced the addition of Global Markets Direct's new report "Addiction - Pipeline Review, H2 2012" to their offering. This report provides information on the therapeutic development for Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Addiction. Addiction - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Addiction. - A review of the Addiction products under development by companies and universities/research institutes based on information derived from com




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 41

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 124

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 97

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 73

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 72

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 117

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 111

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 83

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading

Top 5 Most Recently Viewed Articles

Fluor Corporation Investors Alert: Join the Class Action Now

Updated Category News Views 153

Fluor Corporation Class Action Overview The Portnoy Law Firm has issued an important announcement regarding Fluor Corporation's recent class action lawsuit. Investors who purchased securities of Fluor during a specified period are encouraged to participate. Details of the Class Action This class action is targeting investors who acquired Fluor Corporation shares from...

Continue Reading
Maravai LifeSciences Investors: Are You Affected by Recent Issues?

Updated Category News Views 141

Maravai LifeSciences Holdings, Inc. Overview Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) has quickly become a pivotal player in the biopharmaceutical sector. Their innovative approach and dedication to improving scientific methods have attracted attention from investors and stakeholders alike. However, recent events have thrown some uncertainty into the landscape...

Continue Reading
Gesa Credit Union Acquires Willamette Valley Bank

Updated Category News Views 73

Community Banking Shake-Up in the Pacific Northwest Ah, mergers and acquisitions—they’re like spices in the economic salsa. Today's special? Gesa Credit Union, one of Washington’s powerhouses, deciding to acquire Willamette Valley Bank. Nothing gets the business blood pumping like a good ol' fashioned acquisition. The Financial Backdrop This deal isn't some casual...

Continue Reading
Market Uncertainty Eases as Economic Data Floods In

Updated Category News Views 181

Market Uncertainty Eases as Economic Data Floods In The US government shutdown has come to an end. However, as soon as the funding bill was signed, the markets shifted their focus toward the substantial economic data that has been delayed for over six weeks. This hiatus lasted for forty-three days without any federal reporting, resulting in a significant gap in available...

Continue Reading
AIM Congress 2026: Shaping Future Investment Pathways

Updated Category News Views 510

Exciting News About AIM Congress 2026 The Organizing Committee of AIM Congress, the foremost investment platform globally, has announced the launch of its 15th edition, centered around the compelling theme: Reshaping Global Prosperity: Unlocking New Investment Pathways Towards a Sustainable and Inclusive Future. This prestigious event is set to take place in April 2026 at...

Continue Reading